e.l.f. Beauty, Inc. (NYSE: ELF) — A Share-Gaining Disruptor Whose Moat Is the Price Gap, Now Taxed at the Border and Buying Its Growth

An independent analyst’s research note. The analysis below carries no investment recommendation and no price target. The sole exception is the Analyst’s Take block immediately below, which is one person’s opinion, not investment advice.

⚡ Analyst’s Take

This is the author’s own subjective opinion — general information, not investment advice. The analysis in the sections below takes no position and contains no price target.

Verdict: HOLD / AVOID-adding-here; accumulate-on-weakness only back toward the high-$50s/low-$60s. Not-a-short. Conviction: medium. A directional fair-value zone of ~$58–82 falls out of ~2.1–2.9x forward sales / ~12–15x a believable forward adjusted EBITDA (~$380M) / ~15–18x an owner-earnings number (~$1.75/sh, i.e. adjusted EPS charged for the SBC and earnout it excludes) — which brackets today’s ~$76.42. The point of that overlap is the whole call: after a +54% squeeze off the June-5 low ($49.57), the price has re-inflated back to fair, and the margin of safety that existed at $50 is gone.

The framing is abandoned former-momentum growth name, mid-de-rating, on a sharp counter-trend bounce — not deep value and not a resumed uptrend. e.l.f. is a genuinely excellent operating machine — 29 consecutive quarters of net-sales growth, US mass-cosmetics share up ~920bps in seven years to ~13% (the single largest gainer of ~1,000 tracked brands), ~70% gross margins, 45% unaided awareness up from 13% in 2020, and the #1 brand with Gen Z. But I think the bulls own the wrong moat. e.l.f.'s advantage is the price gap — prestige-quality dupes at $6, funded by a low-cost Asia supply chain — not durable brand captivity. Management proved the distinction itself: the August-2025 $1 price increase (to eat tariffs) produced a “more pronounced decline in units,” and cutting Halo Glow from $18 to $14 drove a +36% unit lift. That is textbook price elasticity — the absence of pricing power. And the price gap is exactly what a ~55% average FY26 China tariff is taxing away. It is not a coincidence that the core e.l.f. brand’s organic consumption decelerated from high-single-digit to low-single-digit (Q4 organic ex-rhode was ~+1%; FY27 organic is guided +4–5% with Q1 down high-single-digits) the moment its price edge narrowed.

Meanwhile the growth is increasingly bought, not built: rhode (Hailey Bieber) cost ~$897M (~4x trailing sales, 57% goodwill), flipping a pristine balance sheet to ~$550M net debt; SBC runs $87M — essentially all of true FCF; GAAP EPS of $0.44 vs. an adjusted $3.13 that itself fell 8% YoY (owner earnings are nearer $1.50–2.00); ROIC collapsed 19%→5.4% (at/below WACC); insiders sold ~$25M and bought zero on the open market through the decline; and management is paid on Adjusted EBITDA and net-sales CAGR — the exact metrics dilutive M&A inflates — with no ROIC or per-share metric anywhere in the plan. rhode and international (~21% of sales, +38%) are real, valuable second acts that give the story a credible bull case — which is why I’m not short a 1.6-beta name that could squeeze further. But at ~2.8x sales and ~24x GAAP EV/EBITDA on ~2% organic volume-negative core growth, you are paying a discretionary-growth multiple for a topline converging toward staples. Cheap vs. its own manic history; not cheap in absolute terms, and no longer cheap after the bounce.

Conviction: medium. Flips bullish if core e.l.f. units inflect positive for two-plus quarters as the pricing/innovation interventions bite and FY27 adjusted EBITDA lands at/above the $385M high end with rhode holding 50%+ growth into its Sephora-Europe rollout — that says the air-pocket was cyclical and the franchise re-rates. Flips bearish if core organic stays ≤2% (or negative) through FY27, adjusted EBITDA margin stalls in the 17–20% zone, and rhode decelerates as it laps the August-2026 acquisition anniversary — which would confirm a structural reset and make ~44x owner-earnings indefensible.

Tag: “The bounce priced out the bargain.”

📈 Stock Price Action — Five-Year Event Map

Price moves are FACT; attributed drivers are INTERPRETATION. No target, no recommendation.

The arc. Over five years ELF ran the full mania-and-crash round-trip: from the low-teens in 2021, to a viral ~$49→$152 melt-up through 2023 (capped by S&P 500 inclusion), to an all-time-high $218 close (2024-06-27), then a ~77% peak-to-trough collapse to $49.57 (2026-06-05) as the growth multiple de-rated and a ~55%-tariff shock hit the low-cost model. Today the stock is $76.42 (2026-07-02) — roughly 65% below its ATH, inside a wide 52-week range of ~$49.57–$146.67, and ~54% above the June-5 low on a sharp counter-trend bounce. It sits in the lower-middle of its own five-year cycle: cheap versus its history, still expensive versus staples peers, and unresolved on direction.

Cycle narrative. (1) 2023 was the making of the story — viral TikTok-era consumption drove the 20%+ streak and S&P 500 inclusion (Sep-2023) forced index buying, roughly tripling the stock. (2) Into mid-2024, beat-and-raise momentum carried the multiple to a mania peak (~10x sales) and the $218 ATH close on 2024-06-27. (3) From that peak, shrinking upside surprises turned the growth premium into a de-rating and the shares roughly halved by early 2025. (4) The April-2025 plunge to ~$50 was the tariff shock crystallizing — a business built on China-sourced value pricing is uniquely exposed, and the market repriced the model, not just the multiple. (5) The ~$50→$147 round trip through September was the rhode-acquisition close (Aug-2025), the offsetting $1 price increase, and a broad relief rally — hype more than fundamentals. (6) That optimism unwound into year-end 2025 as tariff/margin math and decelerating organic reasserted. (7) The Q3 FY26 print sparked a ~25% pop to $94.83 on rhode’s contribution and a resilient guide. (8) The Q4 FY26 print (2026-05-20) — organic ex-rhode just +1%, Q4 adjusted EBITDA down YoY ($59M vs $81M), FY27 organic guided only +4–5% with Q1 down high-single-digits — plus the persistent ~55% tariff overhang drove the shares to a fresh cycle low of $49.57 on 2026-06-05, before a ~54% counter-trend bounce to $76.42 by early July (a squeeze in a still-negative-relative-strength, ~1.6-beta name; inflection or bear rally is unresolved). (Price moves: Fact, from the 5-year CSV. Attributed drivers: Interpretation, cross-referenced to earnings prints, 8-Ks, guidance, and news.)

1. Executive Summary

e.l.f. Beauty is a ~$1.64B-revenue (FY26, ended 2026-03-31), Oakland-based multi-brand mass-beauty company built on one ruthlessly executed idea: sell “prestige-quality” color cosmetics and skincare at drugstore prices — the $6 dupe of a $30 premium product — and let a fast-follower innovation cadence (~26-week concept-to-shelf) plus a viral, low-cost social-marketing engine do the demand generation that legacy players buy with television and department-store gondolas. It has worked spectacularly: net sales compounded from ~$283M (FY20) to $1,636M (FY26), a ~34% CAGR, with 29 consecutive quarters of net-sales growth and US mass-cosmetics dollar share up ~920bps in seven years to ~13% — the single largest share gain of ~1,000 Nielsen-tracked brands. Gross margin is a prestige-like ~70.7%, the clearest financial fingerprint of the model: the price is “mass,” but the Asia-sourced cost is low enough to still undercut prestige while carrying a prestige margin.

FY26 was the year the economics broke, even as the top line kept printing. GAAP operating income fell to $73.6M (4.5% margin) from $158.0M (12.0%), GAAP net income collapsed to $26.3M from $112.1M, and diluted EPS fell 80% to $0.44 from $1.92. Three forces converged: (1) a China-sourcing tariff shock — the average tariff rate roughly doubled to ~55%, directly assaulting the cost gap that is the moat; (2) the rhode acquisition (Hailey Bieber’s brand, closed Aug-2025 for ~$897.5M, ~4x trailing sales, 57% goodwill), which levered a net-cash balance sheet to ~$550M net debt, added ~$35M of intangible amortization and a $57.6M non-cash earnout revaluation, and doubled interest expense; and (3) a stalling core — organic (ex-rhode) growth of just ~2% for the year and ~+1% in Q4, with volumes falling as the August-2025 price increase met a price-elastic consumer.

The investment question is not whether e.l.f. is a good business — the legacy franchise is genuinely excellent, asset-light, high-margin, and share-gaining. It is what e.l.f.'s normalized growth and returns are now that (a) the low-cost model carries a structural tariff tax, (b) the core US mass base has matured to low-single-digit organic growth with negative volume, and © the growth algorithm has shifted from organic share-gain to debt-and-equity-funded M&A (Naturium $333M in 2023; rhode ~$897M in 2025) at deteriorating returns on capital (ROIC 19%→12%→5.4% in two years, now at or below WACC). Management answers with an adjusted-earnings lens — FY26 Adjusted EPS of $3.13 versus GAAP $0.44 — but that $3.13 itself declined 8% from $3.39, and it is reached by adding back ~$87M of recurring stock-based compensation (5.3% of revenue) and the cost of the rhode earnout while keeping all of rhode’s revenue; a defensible owner-earnings figure is closer to $1.50–2.00 per share.

At ~$76.42 (~$4.5B market cap, ~$5.1B EV) the stock trades at ~2.8x sales (the ~16th percentile of its own history — cheapest-ever range after a ~70% multiple de-rating), ~24x GAAP EV/EBITDA, ~13–14x forward adjusted EV/EBITDA, and ~23x forward adjusted P/E on FY27 guidance of +12–14% revenue growth (~9 points of which is simply the rhode annualization) and Adjusted EPS of $3.27–3.32. That is cheap relative to e.l.f.'s manic past and a premium to Estée Lauder, Ulta, and Coty; it is a discretionary-growth multiple on a topline converging toward staples-like organic growth. The bull case — international, rhode’s Sephora runway, category expansion into skin and hair, and tariff pass-through restoring margin — is real but increasingly acquired and international rather than organic-domestic. The bear case — a structurally tariff-taxed value model, decelerating and volume-negative core, growth financed with dilution and debt, and no durable brand moat — is equally live. This memo takes no position on which resolves; the body that follows lays out the evidence for both.

2. Business Overview

e.l.f. Beauty, Inc. is a multi-brand mass-market beauty company whose flagship, e.l.f. Cosmetics, was built to sell prestige-quality color cosmetics and skincare at drugstore prices and let a fast-follower innovation cadence plus a viral, low-cost social-marketing engine generate the demand that legacy players buy with expensive media. The model has produced one of the more remarkable growth records in US consumer: net sales grew from ~$283M in FY20 to $1,636M in FY26 (~34% CAGR), with FY26 up +25% and Q4 FY26 up +35% to $449M, marking the 29th consecutive quarter of net-sales growth — one of only six of 546 tracked US public consumer companies to grow 29 straight quarters averaging ≥20% per quarter (management, Q4-FY26 call, 2026-05-20). Gross margin of 70.7% for FY26 (73% in Q4) is striking for a value-priced mass brand and is the clearest financial fingerprint of the strategy: the price is “mass,” but the sourced cost (predominantly Asia/China contract manufacturing) is low enough that the retail price still undercuts prestige while carrying a prestige-like margin.

Portfolio. e.l.f. is now genuinely a house of brands, and the diversification has been rapid and deliberate. Per the FY26 10-K and Q4 call: (1) e.l.f. Cosmetics — the global flagship, ~$1.8B in global retail sales FY26, the growth and profit engine; (2) e.l.f. SKIN — ~$200M retail sales, the #11 US mass-skincare brand (up from #25 five years ago), holding only ~2% mass-skin share vs. the category leader’s ~13%; (3) Naturium — a clinical/biocompatible skincare brand acquired in 2023 for $333.0M, now ~$250M retail sales, roughly double its pre-acquisition level; (4) rhode — Hailey Bieber’s high-growth, prestige-leaning skincare/lip brand acquired August 2025, delivering >$500M annualized global retail sales and ~$390M net sales, +80% YoY, and already the #1 beauty brand in Sephora North America; and (5) Well People, a smaller clean-beauty brand. Keys Soulcare was transferred back to Alicia Keys in May 2026 and is no longer in the portfolio — a tacit admission it never scaled. The strategic result: non-e.l.f. brands went from 0% to 30% of global consumption in three years, skincare from 9% to 23%, and manufacturing outside China from 1% to over 45% (Q4-FY26 call) — an intentional de-risking of both category concentration and China/tariff supply-chain exposure.

How it makes money / channel & geography. e.l.f. is a wholesaler-plus-DTC. FY26 net sales split 76% national & international retail / 24% e-commerce, and 79% US / 21% international (FY26 10-K, Distribution). Its four largest customers — Target 18%, Walmart 13%, Amazon 11%, Sephora 10% — account for 52% of net sales, a material concentration; Sephora only entered the top four via the rhode acquisition (10-K, Customers). Revenue is generated by selling product into these retailers’ planograms and via DTC (elfcosmetics.com, brand.com sites), with Amazon and TikTok Shop as fast-growing digital nodes. The economics rest on three levers: (a) a low-cost Asia supply chain that funds the ~70% gross margin; (b) a marketing/digital spend of 24% of sales in FY26 (31% in Q4) — very high in absolute terms but delivering outsized awareness because it is social/creator-led rather than TV; and © shelf space at mass retail, where e.l.f. has converted early Target support into category leadership (~21% unit share at Target).

New-category extension is the current growth vector: e.l.f. Hair launched June 2026 (six SKUs ≤$10, TikTok Shop first on 6/16, Target by early July), following two limited-edition hair drops that sold out in 48 hours with 65% new-to-brand buyers (company IR; NewBeauty, June 2026). The skeptical read is that revenue quality is more fragile than the 34% CAGR implies: this is repeat-purchase consumable beauty (good), but demand is trend- and virality-sensitive, retailer relationships are terminable at will (“none of our customers are under any obligation to continue purchasing” — 10-K), and the flagship’s organic momentum is decelerating.

Verdict: A genuinely differentiated, high-growth, high-gross-margin operating model — but one whose revenue quality is more fragile than the headline CAGR implies. The value proposition is real and the multi-brand build-out is credible, yet the business runs on retailer shelf space it does not control, an Asia cost base now carrying punitive tariffs, and a flagship whose organic growth has just moderated sharply — features that make this a strong business model rather than a fortress business.

3. Industry Dynamics

The arena is mass and prestige color cosmetics and skincare, a segment of the ~$500B+ global beauty market. At the category level the economics are attractive and structurally growing: low-to-mid-single-digit secular volume growth plus premiumization, habitual repeat purchase, emotional/aspirational brand equity, low capital intensity, and a long demographic runway (the same tailwinds the Estée Lauder work catalogued). On a Greenwald lens the category has real demand-side characteristics — habit and brand affinity — that can, for the right owner, become captivity. But that is the category, not e.l.f.'s slice of it.

Structure and competitive set. US beauty is concentrated at the ownership level, dominated by a handful of multinationals — L’Oréal, Estée Lauder, Coty, Unilever, LVMH, Shiseido, Beiersdorf, Procter & Gamble — each operating multiple brands (FY26 10-K, Competition). In mass color cosmetics specifically, e.l.f.'s direct rivals are L’Oréal’s Maybelline and NYX, L’Oréal Paris, Coty’s CoverGirl/Rimmel, Revlon, and Markwins’ Wet n Wild, plus private label. Adjacent and increasingly overlapping are the indie/DTC and creator-founded brands (Rare Beauty, Charlotte Tilbury, Glossier, and rhode itself before acquisition) and a rising wave of K-beauty in both skincare and color. The 10-K explicitly flags the low-barrier threat: “small independent companies continue to enter the market with new brands,” and “numerous online, ‘indie,’ celebrity and influencer-backed beauty companies… have emerged and garnered significant followings.”

That last sentence is the crux, and it cuts against e.l.f. as much as for it. The barriers to entry in beauty have collapsed: contract manufacturing (much of it in Korea and China) means anyone can source a competent formula, and social distribution (TikTok, Instagram, creator seeding) means a brand can reach scale audiences without a distribution moat or an advertising war chest. e.l.f. is itself the living proof — it went from masstige challenger to mass-color unit-share leader in roughly three years on exactly this playbook. But the door it walked through remains wide open behind it. rhode did the same thing (zero to >$500M retail as a founder-led DTC brand) and had to be bought rather than beaten. This is a Marathon capital-cycle warning sign: high returns and viral success have attracted a flood of new brands and PE capital into indie beauty — precisely the conditions that precede mean-reverting returns for incumbents and disruptors alike.

The retailer holds the whip hand. In mass, shelf space is a scarce, zero-sum, retailer-allocated resource. Target, Walmart, CVS, and Walgreens decide planogram facings each reset; a brand’s shelf position is both its distribution and its most exposed flank. e.l.f.'s ~21% share at Target (its longest-standing customer) is the moat’s best evidence — but it is a moat rented from Target, revocable at the next planogram, and the same retailers actively cultivate competing brands and private label to preserve their own margin and negotiating leverage. Ulta and Sephora add a specialty layer where e.l.f. (mass) and rhode (prestige-adjacent) both play, but there too shelf and endcap allocation is the retailer’s to give and take. Social commerce as distribution — TikTok Shop, Roblox activations, festival takeovers — is a genuine structural shift that has favored Gen-Z-native brands like e.l.f. and disadvantaged legacy houses reliant on department stores. But it is a rented distribution channel too, governed by an algorithm and a platform (TikTok) with its own regulatory and ownership uncertainties, and equally available to the next viral entrant.

Where the profit pools sit and who is winning. Mass beauty is lower-margin at retail than prestige, but e.l.f. has captured prestige-like gross margins by arbitraging Asia sourcing against a mass price point — a structural edge only as durable as the sourcing-cost gap and the tariff regime. The FY26 average tariff rate of ~55% (double the prior year) is a direct assault on that arbitrage; FY27 guidance assumes 35%. Legacy prestige (EL) is in secular channel decline; L’Oréal is the best-run incumbent and the most dangerous long-term competitor because it owns both the mass brands e.l.f. attacks (Maybelline, NYX) and the derma/skincare and prestige assets, with vastly greater R&D, scale, and the balance sheet to out-spend or out-wait a price war.

Verdict: Structurally mixed — a good category inside a bad competitive structure for any single disruptor. The demographics, repeat-purchase economics, and premiumization are genuinely attractive, and social commerce opened a real growth lane. But entry barriers are low and falling, the shelf is controlled by concentrated, self-interested retailers, virality is fickle, and multinational incumbents have the resources to withstand a price war e.l.f. cannot. This is a structurally attractive category that is structurally hard to defend a position in — the same forces that let e.l.f. win are the forces that make the win contestable.

4. Competitive Position

The central question is whether e.l.f.'s 29 consecutive quarters of growth and 25-plus quarters of share gains reflect a durable moat or a marketing-driven land-grab vulnerable to the next viral brand and to its own supply-chain economics. Applying Greenwald’s taxonomy rigorously, the honest answer is: e.l.f. has a real but narrow and partly rented advantage — best characterized as economies of scale in marketing/community engagement layered on a supply-side (Asia sourcing) cost advantage — but it does NOT have durable demand-side customer captivity (brand loyalty), and that is the vulnerability.

Test 1 — Market-share stability (the strongest evidence for a moat). Greenwald’s most reliable moat test is stable or rising share over a long window. e.l.f. passes emphatically on the historical record: 29 consecutive quarters of net-sales growth, US mass-color share +920bps over seven years to ~13% nationally (+115bps in FY26 alone — the largest gain of ~1,000 Nielsen-tracked brands), ~21% share at Target, the #1 brand among Gen Z, Gen Alpha, and millennials, and unaided awareness up from 13% (2020) to 45% (2025) (Q4-FY26 call; Circana/NIQ data cited by management and corroborated by trade press). Share this concentrated and this persistently rising is not luck. It reflects a genuine scale advantage in the one thing that matters in Gen-Z beauty: cultural relevance produced by a marketing engine (creator seeding, TikTok/Roblox, festival takeovers) that spends ~24% of sales but generates awareness far cheaper-per-impression than legacy TV/department-store models. At e.l.f.'s revenue scale, that engine has a fixed-cost-leverage character — a bigger brand can fund more, and higher-profile, activations — a real, if soft, economies-of-scale-in-demand advantage.

Test 2 — Does the “moat” tie to a financial outcome that deteriorates without it? (Where it cracks.) A moat is only a moat if removing it visibly hurts the numbers. Here the FY26/FY27 data delivers the skeptic’s exhibit A. In August 2025 e.l.f. took a $1 price increase across all e.l.f.-brand SKUs (to absorb tariffs). The demand response: a “more pronounced decline in units” — Q4 units down ~5 points while price/mix added +40 points — and management is now reversing prices, cutting Halo Glow skin tint from $18 to $14 and seeing a +38% unit lift on Amazon, +36% across all retailers, and a triple-digit lift on TikTok Shop (Q4-FY26 call). This is the definition of price elasticity, i.e., the absence of pricing power: consumers buy e.l.f. because it is cheap, and they leave when it is less cheap. A brand with genuine demand-side captivity can raise price without losing volume (see EL’s La Mer). e.l.f. cannot. Its advantage is the price gap itself, not the brand — which means the moat is a cost/supply advantage (Greenwald type 1), and that advantage is precisely what ~55% tariffs are eroding.

Meanwhile the flagship’s organic momentum has visibly rolled over: e.l.f.-brand consumption moderated from high-single-digit to low-single-digit in the last 12 weeks, Spring-2026 innovation got off to a “slower-than-expected start,” Q4 organic (ex-rhode) growth was only ~1%, and FY27 guidance is 12–14% net-sales growth of which 9 points is simply the rhode annualization — implying organic of just 4–5%, with Q1 FY27 organic guided down high-single-digits. After 25-plus quarters of double-digit, share-fueled growth, the core brand decelerated hard the moment it lost its price edge. That is the single most important fact in this section.

Test 3 — Replicability of the model. The fast-follower innovation engine (~26-week concept-to-shelf, dupe-driven) is a process advantage, not a structural barrier — it can be, and is being, copied by any brand with Asian contract manufacturers and a social team. rhode built a >$500M brand doing something adjacent; the next Rare Beauty or K-beauty entrant can too. What is harder to replicate at e.l.f.'s scale is the combination of (a) the installed shelf position at Target/Walmart, (b) the accumulated community/awareness (45% unaided), and © the sheer size of the marketing budget. That bundle is a real advantage — but note (a) is rented from retailers and (b) is a function of continued marketing spend and cultural relevance, both of which decay if the engine stalls. There is no switching cost (beauty consumers are famously promiscuous), no network effect, and no proprietary technology or patent moat.

Direct comparison. Versus L’Oréal’s Maybelline and NYX — e.l.f.'s closest mass-color rivals — e.l.f. has won share, but L’Oréal owns the R&D scale, global distribution, and balance sheet to fund a sustained price/marketing counter-attack, and plays mass and prestige and derma. Versus Wet n Wild (Markwins), e.l.f. has decisively out-executed on brand-building and premium perception at a similar price point — e.l.f. is the higher-quality franchise. Versus prestige (EL, Charlotte Tilbury, Rare Beauty), e.l.f. competes on value and Gen-Z relevance and is taking share, but lacks the pricing power and margin-per-unit that true brand captivity confers — which is precisely why it bought rhode, a genuinely prestige-adjacent, founder-halo brand with real pricing power (rhode raised prices and grew 80%). The rhode acquisition is best read as e.l.f. buying the demand-side moat its own flagship lacks.

Verdict: A real but narrow and eroding moat — scale-in-marketing plus an Asia cost/price-gap advantage, with NO durable demand-side brand captivity. The 25-plus-quarter share record is genuine and hard to dismiss, and at its current scale e.l.f. is not a fragile one-hit brand. But the moat is anchored in being cheaper, and the FY26 price increase proved the demand is elastic and the “brand loyalty” thin; the same event, compounded by ~55% tariffs, produced the flagship’s first serious organic deceleration in years. The durable-share bulls are relying on a moat (brand) e.l.f. does not have while under-weighting the moat it does (cost) — which tariffs are actively degrading. This is closer to a superbly-run fast-follower with a marketing-scale edge than a durably-advantaged franchise; the acquisitions of rhode and Naturium are management’s own implicit acknowledgment that the flagship’s moat needed reinforcement.

5. Growth History and Forward Opportunities

The headline growth machine — and what it conceals. On the surface e.l.f. is one of the great consumer-growth stories of the decade. Net sales compounded $579M (FY23) → $1,024M (FY24, +77%) → $1,314M (FY25, +28%) → $1,636M (FY26, +24.6%), and management closed FY26 touting its 29th consecutive quarter of net-sales growth and its seventh straight year averaging 20%+ growth. That track record is real and should not be dismissed. But the central analytical question is whether organic growth is decelerating sharply as the US mass base matures, with M&A and pricing masking the slowdown. The evidence says yes — emphatically.

Decomposing the growth: organic vs. acquired. This is the single most important thing to understand about ELF today, and it is buried under the headline number:

• FY24 (+77%): Almost entirely organic. Naturium (acquired 10/4/23) contributed only ~5% of FY24 revenue for a partial year. Ex-Naturium organic growth was ~+68%. The core e.l.f. Cosmetics engine was genuinely explosive.
• FY25 (+28%): No new deals; Naturium annualized. Organic still strong, roughly ~20%+.
• FY26 (+24.6%): Here the story breaks. Of the $323.0M revenue increase, $293.5M came from the ~8 months of rhode; the legacy business added only $29.5M — organic growth of ~2.2% (10-K MD&A). Management confirmed the punchline directly: Q4 FY26 net sales grew 35%, but rhode added ~34 points, so organic was up approximately +1% year-over-year.
• FY27 guidance (+12–14%): Management explicitly guides ~9 points from rhode annualization (~$140M in the first four months before it laps into “organic”), with underlying organic ~4–5% — and, critically, Q1 FY27 organic net sales guided down high-single-digits.

So the organic trajectory is: ~68% → ~20%+ → ~2% → ~4–5% guided, with a negative quarter in the mix. The compounding narrative is being sustained by two levered acquisitions and, increasingly, by price.

Growth is now price-led, with units in decline. The quality of even that residual organic growth is poor. In FY26, higher average item price and mix drove +$333.5M of revenue while volume subtracted $10.5M — the annualization of the August-1-2025 global dollar price increase, taken to offset tariffs. For a brand whose entire moat is value, a maturing, price-elastic base where volume goes negative the moment prices rise is a serious structural tell. Management confirmed it in plain language: “we have recently seen a more pronounced decline in units… we are keenly focused on how to deliver a better value and improve unit velocity,” and has already begun cutting prices on hero products.

Forward opportunities — real, but doing heavy lifting. The bull case for re-acceleration rests on four legitimate but unproven vectors: (1) International (~21% of sales vs. L’Oréal 60%+) — the clearest white space; grew +38% in FY26 and +75% in Q4, still under-penetrated in the UK, Canada, Italy, Germany; the highest-conviction leg, but off a small base. (2) rhode (DTC + Sephora rollout) — #1 beauty brand at Sephora North America yet in <20% of Sephora’s global doors, with a September-2026 launch across 19 EU countries and MECCA in Australia/NZ; higher gross margin and a DTC channel e.l.f. historically lacked; the single best growth asset acquired — but acquired, and loaded with key-person/integration risk. (3) Skincare (Naturium, e.l.f. SKIN) — category expansion into a larger, higher-margin adjacency; progressing, but more crowded and less “dupe-able” than color. (4) e.l.f. Hair (June 2026) — a test of whether the value + viral playbook extends beyond color and skin; early signal only, immaterial to FY27.

Verdict: LOW-QUALITY GROWTH at the margin. The headline 20%+ compounding masks a US mass franchise that decelerated from ~68% organic to ~1% in the most recent organic quarter, with volumes now declining and revenue held up only by a tariff-driven price increase. The forward opportunities are genuine and give the story a credible second act, but they are increasingly acquired and international rather than organic-domestic, and they must now do the heavy lifting the maturing core no longer does. This is a growth company transitioning — through M&A — into a slower-growth, roll-up-flavored compounder, and the market is only beginning to reprice that.

6. Financial Quality

The top line still looks spectacular; underneath it, FY26 was the year e.l.f.'s economics broke. Reported net sales grew to $1,636.5M (+25%), the sixth straight year of 20%+ growth. But the composition is the first tell (see the analysis): organic growth was ~2.2%, and it was entirely price/mix (+$333.5M) against falling volume (−$10.5M). After a decade of taking share by adding units at accessible price points, e.l.f. in FY26 grew the base by raising prices against falling volume — a materially lower-quality mix than the “more product on more shelves” flywheel the multiple was built on.

Margins. Gross margin slipped only modestly to 70.7% from 71.2% (−50bp) — tariffs pressured COGS, pricing offset most of it. The damage is below the gross line. GAAP operating income fell to $73.6M (4.5% margin) from $158.0M (12.0%) — roughly halved on 25% higher revenue. Two things drove it: (1) SG&A ballooned +32% to $1,026.1M (63% of sales vs 59%) — marketing/merchandising/distribution +$129.1M, comp/benefits +$55.1M, D&A +$35.0M, professional fees +$20.6M; and (2) a $57.6M non-cash charge for the change in fair value of the rhode contingent consideration, booked because rhode outperformed its earnout thresholds. (Excluding that mark, operating income was ~$131M / ~8.0% margin — still down sharply.) GAAP net income collapsed to $26.3M from $112.1M, and diluted EPS to $0.44 from $1.92 — an 80% decline, amplified by the effective tax rate jumping to 35% from 23% as permanent items (SBC, the analysis(m) comp limits) became a large share of a shrunken $40.5M pretax base.

The GAAP-vs-adjusted chasm is the single most important thing on this file. Management’s Q4 release bridges GAAP net income of $26.3M to Adjusted net income of $185.9M, and GAAP diluted EPS of $0.44 to Adjusted diluted EPS of $3.13 — a 7.1x uplift. The itemized FY26 addbacks:

The addbacks are dominated by two aggressive items. First, SBC of $86.9M (5.3% of revenue) — the largest single addback and a genuine, recurring cost. e.l.f. grants equity to every full-time employee annually; SBC has climbed $40.6M → $71.8M → $86.9M over three years and is why diluted shares keep rising (57.79M → 58.35M → 59.35M) even before the rhode issuance. Adding it back to reach $3.13 treats a persistent transfer of ownership as if it were free. Second, the $57.6M earnout revaluation is added back to net income — i.e., management strips out the cost of owing the rhode sellers up to $200M while keeping every dollar of rhode revenue and profit the earnout is paying for. The better rhode does, the larger the (added-back) charge, and the higher adjusted EPS looks relative to GAAP.

So which number is “real”? Neither. GAAP $0.44 understates true earning power — depressed by a $57.6M non-cash mark and purchase-accounting amortization on assets e.l.f. actually owns. Adjusted $3.13 overstates it — handing back $86.9M of recurring SBC and the earnout cost. A defensible owner-earnings estimate charges SBC as the real cost it is: Adjusted NI $185.9M − after-tax SBC (~$65M) ≈ $121M (~$2.03/sh); charge the earnout accrual too and it drops toward ~$1.50/sh. A cash cross-check agrees: FCF was ~$190.1M (OCF $212.5M − capex $22.4M), but that FCF is itself flattered by adding back the $86.9M non-cash SBC (owner-FCF ≈ $190M − $87M ≈ $103M, ~$1.74/sh), and was further distorted by a +$75.3M accounts-payable swing and depressed by −$47.1M of rhode seller expenses. Triangulating, true per-share economics are on the order of $1.50–2.00 — roughly half the headline adjusted figure. Tellingly, even management’s own preferred metric fell: Adjusted diluted EPS declined to $3.13 from $3.39 in FY25 (−7.7%), and Q4 FY26 printed a GAAP net loss of $(49.4)M with Q4 Adjusted EBITDA down 28% YoY. The adjusted lens, meant to reveal underlying strength, is itself going backwards.

Returns on capital confirm the deterioration. ROIC fell from ~19% (FY24) → ~12% (FY25) → ~5.4% (FY26). Normalizing operating income for the earnout mark (~$131M) yields NOPAT of ~$98M against invested capital of ~$1.68B — still only ~6%, at or below a reasonable ~8–9% WACC. The mechanism: goodwill and intangibles ballooned to $1.41B (59% of the $2.39B balance sheet) after paying ~$897.5M for rhode, so the denominator exploded while incremental NOPAT did not keep pace. The legacy e.l.f. Cosmetics business remains a genuinely good, asset-light, high-return operation; the consolidated entity’s return on the capital shareholders have effectively deployed has been cut by two-thirds in two years.

Balance sheet. e.l.f. entered FY25 essentially net-cash and exits FY26 levered: $289.7M cash against $839.3M funded debt ($30M current + $809.3M term/revolver; $841.7M including finance leases) plus $64.7M of contingent consideration — net funded debt ~$550M, ~$614M including the earnout. The $600M Term Facility (SOFR + 1.50–2.25%) and $500M revolver mature 3/3/30, with a ≥3.50x minimum-interest-coverage covenant. Interest expense more than doubled to $35.3M from $13.8M and steps higher in FY27. Leverage is not dangerous (~1.6x net debt/Adjusted EBITDA) but it removes the balance-sheet optionality that used to be part of the story.

Verdict: economics are deteriorating, not scaling. On the metrics that matter to an owner — GAAP earnings, per-share adjusted earnings, ROIC, and organic volume — FY26 went the wrong way while revenue rose 25%. Gross margin is intact and Adjusted EBITDA margin holds near 20%, so the unit economics of selling cosmetics remain healthy; but the enterprise is now buying its growth (organic +2.2%), diluting owners ~$87M/year through SBC, and earning a mid-single-digit return on the capital tied up in acquired goodwill. The correct read is a high-quality core business whose consolidated returns are being eroded by an increasingly acquisition-and-equity-comp-dependent growth model — economics that get worse, not better, as this version of “scale” is added.

7. Capital Allocation

The defining capital-allocation act of the cycle is the rhode acquisition — a rich, mostly-goodwill deal that levered a previously pristine balance sheet. On 8/5/25 e.l.f. closed HRBeauty LLC (rhode) for an accounting purchase price of $897.5M — ~$590.1M cash + $300.3M stock (2,582,371 shares at $116.28) + a $7.1M initial earnout (max $200M, milestones through 2028) (10-K Note 3). The purchase-price allocation is telling: $380.9M to intangibles (customer relationships $104.6M/12yr + trademarks $276.3M/15yr) and $512.9M — 57% of the price — to goodwill. rhode contributed $293.5M of sales in ~8 months and a ~$391M run-rate, so e.l.f. paid ~2.3x forward sales; against rhode’s ~$212M of sales at signing it paid closer to ~4x, and ~5x including the full earnout — a full price for a three-year-old, celebrity-anchored, single-founder brand whose durability past the founder’s involvement is unproven. Naturium (10/4/23, $333.0M) was the smaller prelude. Two brand acquisitions in 24 months added $1.4B of goodwill and intangibles and are the direct cause of the ROIC collapse. This is textbook Marathon “capital-cycle” behavior: a company earning high returns and trading at a high multiple using that currency (stock at $116) and cheap debt to buy growth — precisely the conditions under which acquirers overpay and returns mean-revert.

Financing the deal flipped the capital structure. e.l.f. raised a $600M term loan and drew the revolver, moving from roughly net-cash to ~$550M net funded debt plus $64.7M of contingent consideration. There is no dividend (the credit agreement restricts one), so all shareholder return runs through buybacks — which brings the second problem.

Buybacks do not offset dilution; they barely dent it. Under the $500M authorization (8/27/24), e.l.f. has repurchased only ~$117M ($50.0M in FY26 at ~$79.8; $67.1M in FY25), with ~$383M remaining. Against that, SBC ran $86.9M in FY26 and the company issued 1.4M shares to option/RSU vesting plus 2.58M for rhode. Net: issued shares rose from 55.73M to 59.09M (+6%) and diluted shares from 58.35M to 59.35M. Even excluding the acquisition, equity comp alone out-issues the buyback. The buyback functions as a partial SBC-mop, not per-share value creation — management spends real cash (~$50M/yr) to slow, not stop, the dilution its own comp model creates.

The incentive design is the root cause, and the sharpest criticism here. Per the DEF 14A (7/9/25): the annual cash bonus is tied solely to Adjusted EBITDA (FY25 target $286.0M); the PSUs (50% of executive equity, 3-year cliff) are tied to 3-year net-sales CAGR and Adjusted-EBITDA CAGR, plus a 25% kicker for e.l.f. Cosmetics market-share gains. There is no ROIC, no return-on-capital, no per-share, and no GAAP-earnings metric anywhere in the plan. That is exactly the wrong scorecard for a company now deploying capital into large acquisitions: buying rhode mechanically raises net sales and Adjusted EBITDA (the paid-on metrics) while cratering ROIC and diluting per-share value (the un-measured outcomes). Both the $57.6M earnout revaluation and the $86.9M SBC that gut GAAP EPS are added back inside Adjusted EBITDA, so the metric management is paid on is insulated from the two costs that most burden owners.

In fairness, several things are genuinely well-run. Base cash compensation is strikingly restrained: CEO Tarang Amin’s salary has been $475K since 2014 and his FY25 total was $8.83M, ~94% variable and heavily equity. The company avoids the empire-building tell of fat guaranteed cash. Marketing and speed-to-market innovation — the engine of the legacy franchise — are appropriately funded. And the M&A, while richly priced, is strategically coherent — extending from mass color into skincare (Naturium) and a higher-price “prestige-accessible” lifestyle brand (rhode) that broadens the addressable market and demographic. If rhode compounds and the earnout is fully earned, the price will look defensible in hindsight.

Verdict: capital allocation has turned from a strength into a swing factor, tilted negative. For most of its public life e.l.f. compounded organically with a clean balance sheet and disciplined comp. In this cycle it used peak stock and new debt to pay a full ~4x-sales price for a founder-dependent brand (57% goodwill), levered to ~$550M net debt, pays a buyback that fails to offset its own dilution, and — most damningly — rewards management on the very growth-and-EBITDA metrics that dilutive M&A inflates while ignoring the returns on capital those deals are destroying. Management has not yet clearly allocated this capital intelligently; the rhode thesis is unproven, the returns math is currently poor, and the incentive structure does not protect owners if it stays that way. This is now a “prove-it” on capital allocation, not a track record to underwrite.

8. Changes and Headwinds — Last Two Years

The last 24 months have been the most eventful — and most thesis-altering — in ELF’s public life: two acquisitions, a structural tariff shock, a guidance withdrawal, a margin reset, and a ~77% peak-to-trough drawdown.

The rhode acquisition (announced 5/28/25; closed 8/5/25). A ~$897.5M accounting-price deal (~$590M cash + $300M stock + $7.1M initial earnout, max $200M) for Hailey Bieber’s brand, with Bieber becoming Chief Creative Officer / Head of Innovation. Strategically coherent (higher margin, DTC, prestige-channel access, a second demographic) but a large, debt-funded bet on a celebrity-founder brand barely three years old, materially raising key-person, integration, and goodwill-impairment exposure.

The Naturium acquisition (10/4/23, $333.0M). A skincare tuck-in that anchored e.l.f.'s move into clinical/affordable skin — fully integrated, now part of the “organic” base, and the beginning of the M&A-as-growth pattern rhode extended.

The China-sourcing tariff shock (2025–26) — the defining structural change. The majority of e.l.f.'s product is manufactured in China (management/press cite ~75–80% historically), subject to a 25% US tariff since 2019. Beginning early 2025 the US administration stacked additional tariffs; rates peaked at roughly 145%+ in April–May 2025 before settling, such that ELF navigated an average tariff rate of ~55% across FY26 — more than double the prior year. The response: (1) a global $1 price increase (8/1/25); (2) an aggressive supply-chain diversification taking manufacturing outside China from ~1% to over 45%; and (3) ~$58.5M of IEEPA tariffs paid, now the subject of a refund pursuit after the February-2026 Supreme Court ruling invalidating the IEEPA tariffs (refund timing/amount “highly uncertain,” per the 10-K). This is a semi-permanent hit to the cost structure underpinning the entire value proposition — FY26 adjusted EBITDA grew only 13% on 25% sales growth, and Q4 adjusted EBITDA fell to $59M from $81M.

Guidance withdrawal. In August 2025 (Q1 FY26 print), amid the tariff chaos, e.l.f. withheld full-year FY26 guidance entirely, citing a “wide range of potential outcomes,” issuing only a first-half outlook. Guidance was reinstated with the FY27 outlook (+12–14% sales; adjusted EBITDA $379–385M) — a meaningful signal of the environment’s unpredictability, even if now behind them.

The ~77% drawdown and coverage. The stock round-tripped from the ~$218 ATH (June 2024) to $49.95 (April 2025), recovered to $146.67 (September 2025), fell again to a $49.57 low (June 5, 2026), and sits near ~$76 today — down ~46% over twelve months but +54% off the June low. Bernstein initiated at Market Perform, $60 PT (June 12, 2026) — a telling “show-me” stance from the first major new coverage.

Leadership / index. Stable: Tarang Amin (Chairman & CEO) and Mandy Fields (SVP & CFO) remain in seat — no C-suite turnover, a positive. S&P 500 inclusion came September 2023. No material litigation surfaced beyond ordinary course.

Verdict: NET WEAKEN the thesis. The tariff shock is a genuine, semi-permanent impairment to the low-cost model at the heart of the moat, and it arrived just as the organic base stalled — a bad combination. Two debt-funded acquisitions converted an organically-compounding balance sheet into a levered, goodwill-heavy one, trading balance-sheet quality for growth optics. The offset — rhode is a real, higher-margin, DTC-and-prestige growth asset, supply-chain diversification is progressing impressively, and leadership is intact — is meaningful but does not fully counter the structural cost hit plus volume stall. On balance the last two years have made ELF a lower-quality, higher-risk business than the one that traded at $218.

9. Risk Analysis

Verdict. The risk profile is skewed and increasingly structural, not idiosyncratic. Risks #1 and #2 — the tariff-driven impairment of the low-cost model and the organic/unit deceleration — are both High/High and mutually reinforcing: the tariff hit forces price increases into a value brand precisely when its base has become price-elastic enough that volumes fall. Layered on top are a rich valuation (#3), real retailer concentration (#4), and a celebrity-brand/integration bet (#6/#7) that traded balance-sheet quality for acquired growth. There is no near-term solvency risk, but the quality and durability of the franchise are materially more questionable than the 29-quarter streak suggests — the ~77% round-trip is an accurate reflection of a genuinely elevated, structural risk load.

10. Valuation Discussion (Embedded Expectations)

The central problem: GAAP earnings are uninvestable as a valuation anchor, and the adjusted bridge is unusually wide. At ~$76.42 (2026-07-02), e.l.f. carries a market cap of ~$4.5B on ~59.1M shares (~59.35M diluted), and — with ~$839M funded debt against $290M cash and a $65M earnout liability (net ~$614M) — an enterprise value of ~$5.1B. FY26 GAAP diluted EPS was $0.44, so trailing GAAP P/E is meaningless. The entire valuation must be built on cash-and-scale proxies — EV/Sales, EV/EBITDA (GAAP and adjusted), P/S, adjusted P/E, and FCF — with a hard eye on the quality of the “adjusted” figures.

The multiple stack at today’s price:

Reading the adjusted bridge is the whole game. Adjusted EBITDA of ~$327M sits ~$116M (~36%) above GAAP EBITDA of $210.6M; the largest single add-back is SBC (~$87M). SBC is a real, recurring cost that dilutes shareholders whether or not it flatters “adjusted” profit. Net the ~$87M out and true owner FCF is closer to ~$100M, not the ~$190–260M the reported cash lines suggest. On that owner-earnings base the market is paying ~44x; on the adjusted/reported base, ~23x. That fork — 23x if you accept the adjustments, ~44x if you don’t — is the valuation argument in one number. A skeptic anchors to EV/Sales and GAAP EV/EBITDA (where ELF looks fully-to-richly priced) and treats the sub-14x forward adjusted EV/EBITDA as flattering.

Versus its own history, ELF is genuinely cheap — for the first time. ROIC’s decade of multiples shows the froth: FY24 (peak) traded at ~10.5x P/S and ~61x EV/EBITDA; FY23 at ~7.5x P/S. Today’s ~2.8x P/S sits at roughly the 16th percentile of ELF’s own range — only FY2020 and the March-2026 print were lower. The multiple has compressed ~70–75% from the 2024 mania. The question is whether that de-rating is the market correcting an absurd multiple or over-shooting a still-good business — the answer depends entirely on whether growth re-accelerates or has structurally reset.

Versus the peer set, ELF is priced as growth, not a cheap staple. On TTM figures: Estée Lauder ~2.2x EV/Sales / ~13.5x EV/EBITDA (depressed turnaround); Ulta ~2.0x EV/Sales / ~13.6x EV/EBITDA (mature retailer); Coty ~0.9x EV/Sales / ~6.7x EV/EBITDA (distressed, over-levered); L’Oréal — the quality benchmark — ~5x sales, high-teens EV/EBITDA, ~28x P/E. ELF’s ~3.1x EV/Sales is a clear premium to EL/ULTA/Coty and a discount to L’Oréal; its ~13x forward adjusted EV/EBITDA is roughly in line with EL/ULTA, but its ~24x GAAP EV/EBITDA is nearly double theirs. The market is still awarding ELF a growth premium on sales while its organic growth (Q4 ex-rhode +1%, FY27 organic guided +4–5%) has converged toward staples-like. That is the core tension.

Sum-of-the-parts supports the “you’re paying up for rhode/Naturium optionality” read. rhode (~$390M net sales, +80%, #1 in Sephora NA, <20% of doors) plausibly commands 4–6x sales = ~$1.6–2.3B. Naturium and the balance of skin/international add further growth-brand value. Back those out and the residual for the core e.l.f. Cosmetics brand — the ~$1.2B, +1%-organic engine facing a 55% tariff — is modest, arguably 1.5–2.5x sales. At $76 the market underwrites rhode/Naturium as the growth engine and core e.l.f. as an ex-growth, tariff-squeezed cash cow. The debate is whether that split is too generous to rhode (viral-brand durability) or too harsh on core e.l.f. (pricing/innovation could re-accelerate units).

Embedded-expectations scenario framework. Explicit assumptions; per-share equivalents are illustrative embedded-expectations outputs, not targets or recommendations. Base year FY26 revenue $1,636M, adjusted EBITDA $327M; ~60M shares; net debt ~$614M; 5-year horizon.

What must be true at ~$76 / ~$5.1B EV. The current price sits between the bear and base outcomes — roughly what you get from low-double-digit revenue growth decelerating toward high-single-digit, adjusted EBITDA margins recovering only to ~19–20% (not the ~23–24% pre-tariff peak), and a terminal multiple drifting toward the low-teens. The market is underwriting FY27’s ~13% growth guide, then a fade — it is not paying today for a re-acceleration of the core brand, nor for rhode to keep compounding at 80%. Reverse-engineered on FCF, to justify ~$4.5B of equity at a ~10% cost of equity (a 1.6-beta name) and ~3% terminal growth, the market must believe in ~$330M of steady-state levered FCF — which requires the adjusted cash-flow figure to be real (i.e., that the ~$87M SBC add-back is a value transfer the market will look through). The market is pricing the adjustments as legitimate and the deceleration as manageable; it is not pricing either a tariff-driven structural margin reset or a viral-brand disappointment. Those are the two ways the bear case gets paid.

Verdict. On its own history, ELF is at a genuine trough multiple (~16th-percentile P/S) after a ~70% de-rating. On absolute and peer terms it is not cheap: a ~3.1x EV/Sales, ~24x GAAP EV/EBITDA business whose organic growth has fallen to ~1%. The stock is inexpensive if you believe the adjusted numbers and a growth re-acceleration; fully-to-richly priced if you weight GAAP earnings, the SBC drag, and structurally higher tariffs. The valuation is a bet on which of those two ELFs is real.

11. Variant Perception

Consensus. Sell-side has migrated from cheerleader to fence-sitter. The 2024 narrative — “the next great beauty compounder, taking share forever” — collapsed with the multiple. By mid-2026 the tone is explicitly neutral: Bernstein initiated at Market Perform ($60) in June 2026, emblematic of a Street that now frames ELF as a “prove-it” story: great long-run track record, but a decelerating core, a debt-and-dilution-funded rhode acquisition, and an unresolved tariff overhang. Consensus roughly accepts the FY27 guide and treats the shares as fairly valued on ~13–14x forward adjusted EV/EBITDA / ~23x adjusted P/E — neither underwriting a re-rate nor calling a blow-up. The factor tape confirms the ambivalence: momentum loading has collapsed to ~zero (below), meaning the systematic momentum crowd has already left.

The strongest bull case. ELF remains a structurally advantaged share-gainer caught mid-cycle. (1) Still early on international — grew 38% in FY26, a small fraction of sales; the model that dominated US mass has barely begun abroad. (2) Category expansion — skin (Naturium) and hair extend the ~$1.2B color base into far larger TAMs. (3) rhode optionality is underappreciated — ~$390M net sales, +80%, #1 in Sephora NA, in <20% of global doors; a multi-year distribution runway on a brand that is over-delivering. (4) Margin recovery is mechanical — FY26 absorbed a ~55% tariff; the $1 price increase and the shift out of China (1%→45%) mean tariffs get passed through and diluted over FY27–28, with management guiding adjusted EBITDA to $379–385M. (5) Cheapest-ever on sales (~16th-percentile P/S), ~65% off the ATH — a quality franchise on the clearance rack for the first time. The bull says the June low was capitulation and the 29-quarter engine hit a tariff-and-integration air pocket.

The strongest bear case. The GAAP numbers, not the adjusted ones, are telling the truth. (1) Organic growth has structurally reset — ex-rhode, Q4 organic was +1%; Q1 FY27 organic guided down high-single-digits; the headline +12–14% FY27 growth is almost entirely rhode’s inorganic contribution — buy-the-growth, not build-it. (2) The tariff exposure is structural — a brand built on China-sourced value pricing faces a ~55% regime; passing it through risks the value proposition that is the moat, and units are already falling. (3) Growth is financed with debt and dilution — ~$550M net debt, SBC ~$87M/yr, GAAP EPS of $0.44 is what’s left after those real costs. (4) No durable moat against the next viral brand — ELF’s edge is speed-to-trend and value, both replicable; rhode itself proves a creator brand can erupt from nothing. (5) High-beta, momentum-crowded wreckage — beta ~1.6, max drawdown −77%, down ~41% over the trailing year; the +54% bounce may be a bear rally.

The 3–5 assumptions that actually matter: (1) Is core e.l.f. organic of ~1% a trough or the new normal? (2) Are tariffs a one-time reset or a permanent margin ceiling? (3) Does rhode durably compound, or is it a founder-brand fad? (4) Are the “adjusted” numbers legitimate owner earnings (the ~$87M SBC question)? (5) Does the high-beta, ex-momentum tape mean-revert up with risk appetite or resume the downtrend?

Falsification. Bull is falsified if: core organic stays ≤2% (or negative) for 2–3 more quarters despite the interventions; adjusted EBITDA margin fails to recover above ~20% in FY27; or rhode decelerates sharply as it laps the acquisition (Aug-2026). Bear is falsified if: core units inflect positive as the $1 pricing anniversaries and new innovation ships; FY27 adjusted EBITDA lands at/above the $385M high end with margin expansion; international sustains 30%+; and rhode holds 50%+ growth deeper into Sephora. The next 2–3 prints (Q1 FY27 = the shipment-lap trough by design; Q2–Q3 = the real tell on core units and margin) are the resolution points.

Factor-positioning read (a quantitative factor model, 2026-07-02). ELF is empirically a high-beta, idiosyncratic, ex-momentum discretionary name — not a defensive staple. Market beta ~1.53–1.61 (highest-decile); alpha −0.43; R² only ~18–24%, so ~75%+ of variance is stock-specific (it trades on its own story). In the Base model the live style loadings are SmallSize +1.13 and Liquidity +0.68 (a smaller, liquidity-sensitive profile), Quality +0.29 (modest), Momentum −0.03 (≈zero) — the 2023–24 momentum signature fully unwound — and LowVolatility −0.64 (explicitly anti-defensive; it behaves like a risk-on vehicle despite the “Consumer Defensive” GICS tag). The risk-adjusted record maps the round-trip: 5-year +22%/yr (Sharpe 0.35) but 3-year −12%/yr (Sharpe −0.21) and 1-year −41% (Sharpe −0.63), max drawdown −77%. Relative strength is deeply negative (rs_12m −39.7%, rs_peak −64.9%). The recent action is a sharp counter-trend snap: the 3-month figure annualizes to +144% — de-annualized, a ~+25% actual quarter, the squeeze off the June-5 low, not a resumed uptrend (6-month return ~flat). Factor-similar peers (ONON, DECK, CPRI, WYNN, PVH, W, WSM, BBWI, FIVE, EL) confirm the classification: volatile consumer-discretionary momentum/growth names, not staples — cross-checking the the analysis warning that a staples multiple/label understates ELF’s cyclicality. The positioning read for Variant Perception: ELF is an abandoned former-momentum growth name mid-de-rating, now bouncing hard. Consensus may be offsides either way — the momentum crowd has fully exited (so upside is under-owned if fundamentals inflect), but the −77%-drawdown / 1.6-beta profile means a failed inflection reopens substantial downside. Whether the June low is the bottom or a bear-market rally is unresolved by the tape alone.

12. Fact vs. Interpretation

13. Open Questions

1. Is core e.l.f. organic of ~1% a trough or the new run-rate? The pricing reversals (Halo Glow) and Spring/Fall innovation are the near-term tell; two quarters of positive units would answer it.
2. Where does the tariff rate settle, and is the $58.5M IEEPA refund collected? FY27 guide assumes 35%; the refund is a potential one-time cash benefit of uncertain timing.
3. Does rhode’s ~80% growth durably survive lapping the acquisition (Aug-2026) and the founder’s ongoing involvement? Much of the SOTP value and headline growth rides on it.
4. What is the true steady-state SBC ratio? ~5.3% of revenue is high; does it scale down as the company matures, or is “equity for every employee” permanent?
5. Will the board ever add a return-on-capital metric to comp? Absent that, the incentive to keep buying growth at low ROIC persists.
6. How much shelf can international + rhode actually win before hitting the same maturity the US core just hit?

14. What Must Be True

Bull case — what must be true:

• Core e.l.f. units inflect positive within 2–3 quarters as pricing/innovation interventions bite (i.e., the elasticity problem was a one-time price-hike shock, not a maturing base).
• Tariff pass-through + the shift out of China restores adjusted EBITDA margin toward ~23–24% over FY27–28.
• rhode holds 50%+ growth into its Sephora-Europe/MECCA rollout and international sustains 30%+, keeping consolidated growth in the low-double-digits organically.
• Falsification test: two consecutive quarters of core e.l.f. organic ≤2% or negative despite the interventions, OR FY27 adjusted EBITDA margin stuck ≤20%, breaks the bull case — it would confirm the deceleration is structural, not cyclical.

Bear case — what must be true:

• The ~55% tariff is a permanent tax on the price-gap moat, keeping the value brand caught between margin and volume indefinitely.
• Core organic stays low-single-digit or negative, so the enterprise’s growth is permanently dependent on serially buying brands at low ROIC and diluting owners ~$87M/yr.
• rhode decelerates as a founder-brand fad once it laps the acquisition, and/or takes a goodwill impairment.
• Falsification test: core units turning positive AND FY27 adjusted EBITDA landing at/above $385M with margin expansion AND rhode >50% would break the bear case — it would show the low-cost model survived the tariff and the franchise still compounds.

APPENDIX A — Standard Diligence Questionnaire

e.l.f. Beauty, Inc. (NYSE: ELF) — supplemental to the research memo. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The dominant debate is organic-vs-acquired growth: how much of the 20%+ headline is the core e.l.f. brand versus Naturium/rhode M&A and price increases (answer: FY26 organic ~2.2%, Q4 ~+1%). Others: (a) whether the ~55% China tariff permanently impairs the low-cost model; (b) whether adjusted EPS ($3.13) or GAAP ($0.44) is “real” given ~$87M SBC; © whether rhode is worth ~4x sales for a founder-dependent brand; (d) whether the ~13% mass-cosmetics share is durable against the next viral entrant; and (e) whether the incentive plan (Adj-EBITDA/net-sales, no ROIC) encourages value-destructive M&A.

Cyclicality & Earnings Nature

Cyclical high or low? Interpretation: margins are at a cyclical/structural low (op margin 4.5% GAAP vs 12% prior; adjusted EBITDA margin 20% vs 23%) driven by the tariff shock — but organic growth may be at a structural inflection down, not a cyclical trough. External or internal drivers? Both: tariffs are external; the elasticity-driven volume decline and the M&A-dependence are internal/structural. Revenue stability? Repeat-purchase consumable beauty is fairly stable in aggregate, but individual-brand demand is trend/virality-sensitive. Market size/outlook? Global beauty ~$500B+, growing low-to-mid-single-digit; e.l.f. is a share-gainer within mass color/skin, with international and skincare as the larger forward TAMs. Growing, primarily US today (79%) with international (21%) the expansion vector.

Business Quality & Competitive Moat

Industry more or less competitive? More — barriers to entry have collapsed (contract manufacturing + social distribution); indie/creator/K-beauty entrants proliferate. How profitable (ROIC/ROE)? Legacy core is a high-return, asset-light business; consolidated ROIC fell to ~5.4% (FY24 ~19%) as acquired goodwill ballooned the denominator — now at/below WACC. Industry profitability / barriers? Attractive category economics (~70% GM for e.l.f.) but weak positional barriers; concentrated multinational incumbents (L’Oréal, EL) and self-interested retailers control the shelf. Easily understood? Yes. Undermined by low-cost labor? It depends on Asian low-cost sourcing — and that dependence is now the tariff vulnerability. Do brands matter? Yes, but e.l.f.'s edge is value/price gap, not brand pricing power (units fell on the $1 hike). Nature of competition: shelf-space and social-relevance driven. Switching costs: effectively zero — beauty consumers are promiscuous.

Financial Condition & Balance Sheet

Assets not on the balance sheet? The marketing engine / community / awareness (45% unaided) is a real unrecognized intangible. Off-balance-sheet liabilities? Operating/finance leases are on-sheet; the ~$200M max rhode earnout is partly recognized ($64.7M) and partly contingent. Conservative accounting? Interpretation: GAAP is conservative (expenses the earnout mark, amortizes intangibles); the adjusted presentation is aggressive (adds back recurring SBC and the earnout). CapEx-hungry? No — capex ~$22M (1.4% of sales); asset-light.

Capital Allocation & Management

FCF generation and use? ~$190M reported FCF (~$100M owner-FCF net of SBC); used for ~$50M buyback (which fails to offset dilution) and de-levering post-rhode; no dividend. Philosophy: organic-plus-M&A growth; increasingly M&A-reliant. Significant acquisitions? Naturium ($333M, 2023) and rhode (~$897.5M, 2025). Buying back shares? Yes but modestly (~$117M of a $500M authorization) — net share count still rising +6%. Issuing shares to insiders? Yes — SBC ~$87M/yr to all employees; 2.58M shares issued for rhode. Comp policy: restrained cash (CEO salary $475K since 2014), heavily equity/variable, but tied to Adj-EBITDA and net-sales CAGR with no ROIC/per-share metric — the key governance flaw. Management motivation: Interpretation: paid to grow the pie by any means; insiders own only ~3.9% and are structural net sellers of grants.

Valuation & Market Data

ADR/MLP/K-1? No — US common stock, single class. Dividend policy? None (restricted by the credit agreement). How profitable? ~70% gross margin, ~20% adjusted EBITDA margin; GAAP net margin collapsed to 1.6% on tariff/deal costs. Net income diverging from CFO? Yes — GAAP NI $26.3M vs OCF $212.5M; the gap is SBC ($87M), D&A ($79M), and the non-cash earnout mark ($57.6M). Cash generation materially exceeds GAAP earnings, but owner-FCF (net of SBC) is far below reported FCF.

Risks & Downside

What would cause a decline? A core-organic miss or negative quarter; adjusted EBITDA margin failing to recover; a rhode deceleration/impairment; a tariff escalation; a retailer shelf reset; or simple multiple de-rating on a 1.6-beta name. Catastrophic loss risk? Low — diversified distribution, real brands, positive FCF, ~1.6x leverage. Total loss? Very unlikely; the risk is de-rating and growth disappointment, not insolvency.

Recent News & Events

Environment changed recently? Yes materially — the ~55% China tariff shock and the SCOTUS IEEPA invalidation (Feb-2026, refund pending); the rhode close (Aug-2025); a full-year guidance withdrawal (Aug-2025) then reinstatement (May-2026). Significant acquisitions? rhode (2025). Accounting-policy changes? None material; heavy purchase-accounting effects from rhode. Other recent changes? e.l.f. Hair launch (Jun-2026); rhode Sephora-Europe rollout across 19 countries (Sep-2026); Keys Soulcare divested back to Alicia Keys (May-2026); Bernstein initiated Market Perform (Jun-2026); a ~54% price bounce off the June-5 low.

APPENDIX B — Source Appendix

e.l.f. Beauty, Inc. (NYSE: ELF). Primary sources first. Accessed 2026-07-03.

Primary — SEC filings (EDGAR, CIK 0001600033)

• FY26 Form 10-K (period ended 2026-03-31; filed 2026-05-21) — business, segment/channel/geography, competition, risk factors, MD&A (organic vs. acquired growth decomposition; tariff disclosure; price/volume bridge), financial statements & notes (Note 3 rhode purchase-price allocation; SBC; contingent consideration; credit agreement). (local filing archive)
• Form 10-K’s FY22–FY25 — multi-year revenue, margin, EPS, share-count history. (local filing archive)
• Q4/FY26 earnings 8-K (2026-05-20) Ex-99.1 — GAAP→adjusted reconciliations (Adjusted net income $185.9M, Adjusted EPS $3.13), FY27 guidance. (local filing archive)
• 10-Q corpus (FY24–FY26) — quarterly cadence, rhode consolidation timing. (local filing archive)
• 8-K corpus — material-event timeline: buyback authorization (8/27/24), rhode financing / $600M Term Facility (Aug-2025), quarterly prints, tariff/SCOTUS period (Feb-2026). (local filing archive)
• DEF 14A proxy (filed 2025-07-09) — executive compensation structure; bonus tied to Adjusted EBITDA; PSUs on net-sales CAGR + Adjusted-EBITDA CAGR + market-share kicker; CEO salary history; board independence. (local filing archive)
• Form 3/4/4-A corpus (81 filings since 1/1/25) — insider transactions: 31 sales (S), 11 grants (A), 8 gifts (G), 3 exercises (M), 0 open-market purchases (P); CEO Amin ~$12.25M sold; coordinated 6/5 & 6/11/26 vest-settlement sells; Form-144s 7/1/26. (local filing archive)

Primary — earnings-call transcripts (third-party financial data)

• Q4 FY26 call (2026-05-20) — Tarang Amin (Chairman/CEO), Mandy Fields (CFO): FY26 +25% net sales / +13% adjusted EBITDA; core e.l.f. consumption HSD→LSD; Q4 organic +1%; $1 price increase (8/1/25) and unit declines / Halo Glow price cut; China production 1%→45%+; rhode >$500M retail / $390M net sales; FY27 guidance (+12–14% sales; adjusted EBITDA $379–385M; adjusted EPS $3.27–3.32; adjusted tax 25–26%; ~60.5M diluted shares).
• Q3 FY26 call (2026-02-04) and prior FY26 quarters — guidance withdrawal/reinstatement context, tariff commentary.

Quantitative data feeds

• third-party financial data — multi-year income statement, balance sheet, cash flow, profitability ratios (ROIC/ROE/margins), enterprise value, valuation multiples (own-history percentile context). Third-party aggregated; reconciled to the 10-K.
• own-history valuation percentile data (2026-07-02) — own-history percentile ranks: P/S 2.78x (~16th pctile), P/B 4.05x (~27th pctile), composite ~34th pctile; latest price/EPS/book/sales.
• 5-year daily price history — OHLCV, adjusted prices, EMAs, beta — basis for the Five-Year Event Map (ATH $218 close 2024-06-27; June-5-2026 low $49.57; $76.42 on 2026-07-02).
• a quantitative factor model (2026-07-02) — factor loadings (Market beta ~1.6, Momentum ~0, LowVol −0.64, SmallSize +1.13), leaderboard (y1 −41%, y3 −12%/yr, max DD −77%, m3 +144% annualized), stock-info (RS metrics), related-stocks (ONON, DECK, CPRI, WYNN, PVH, W, WSM, BBWI, FIVE, EL).

Secondary — media & analyst

• CNBC — “e.l.f. Beauty to acquire Hailey Bieber’s rhode in $1 billion deal” (2025-05-28).
• CNBC — “e.l.f. Beauty Q1 profit −30%, pulls guidance” (2025-08-06).
• BusinessWire / NewBeauty — e.l.f. Hair launch (June 2026).
• Benzinga — Bernstein initiates Market Perform, $60 PT (2026-06-12); “e.l.f. Beauty Shows Exceptional Strength” momentum note (2026-06-16).
• Circana / NIQ (Nielsen) mass-cosmetics share data as cited by management and trade press.